Contraindications for Tirzepatide
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). 1, 2, 3, 4
Absolute Contraindications
The primary contraindication is based on the FDA black box warning shared across GLP-1 receptor agonist-based therapies:
- Personal history of medullary thyroid carcinoma
- Family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
This contraindication stems from rodent studies showing thyroid C-cell tumors, though human relevance has not been definitively established. Thyroid C cells express GLP-1 receptors, creating theoretical risk in susceptible individuals. 2
Clinical Situations Requiring Extreme Caution or Avoidance
While not absolute contraindications, the following warrant serious consideration against tirzepatide use:
History of Pancreatitis
Though data remain conflicting and causality is not established, consider alternative antihyperglycemic therapies in patients with prior pancreatitis. 1 Interestingly, tirzepatide has been indicated as safe regarding pancreatitis risk specifically, but it does increase risk of gallbladder and biliary disease. 2
Severe Gastrointestinal Disease
Tirzepatide can cause severe gastrointestinal disorders including severe constipation and small bowel obstruction/ileus progression. 3, 4 Recent case reports document functional small bowel obstruction even in surgically naïve patients. 5
Pregnancy
While not explicitly stated as an absolute contraindication in the provided evidence, GLP-1 receptor agonist-based medications require careful consideration in pregnancy, and females using oral contraceptives should switch to non-oral contraception methods for 4 weeks after initiation and each dose escalation due to delayed absorption effects. 3, 4
Important Safety Monitoring
Monitor for delayed absorption of oral medications, particularly those with narrow therapeutic indices (such as warfarin), as tirzepatide affects gastrointestinal motility. 3, 4
Screen for gallbladder and biliary disease risk, as tirzepatide increases cholelithiasis and gallstone-related complications. 2
Common Pitfalls to Avoid
- Do not routinely monitor calcitonin levels in patients taking tirzepatide—the FDA has stated this is unnecessary. 1
- Do not confuse relative cautions with absolute contraindications—only MTC history (personal/family) and MEN 2 are true contraindications
- Do not overlook medication history when patients present with gastrointestinal symptoms, as tirzepatide can cause functional obstruction mimicking mechanical obstruction 5